StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX – Free Report) in a research report sent to investors on Monday. The firm issued a sell rating on the stock. Separately, Cantor Fitzgerald reaffirmed an overweight rating and set a $2.50 target price on shares of VolitionRx in a research report on Thursday, May 16th. Get […]